The probability of revision sinus surgery including the removal of nasal polyps is higher if the patient has asthma or is on antibiotics at the time of their initial surgery. However, higher age was ...

Antrochoanal polyps (ACPs) are benign, solitary lesions that originate from the mucosa of the maxillary sinus and extend into the nasal cavity towards the choana. They can present with unilateral ...

The approval for the CRSwNP indication was based on data from the randomized, double-blind, placebo-controlled WAYPOINT trial.

SAN DIEGO -- Novel ultra-long-acting biologic depemokimab reduced nasal polyps in chronic rhinosinusitis, two parallel phase III trials showed. Twice-yearly injections cut total nasal polyps score by ...

Biologic drugs are a newer treatment option for chronic rhinosinusitis with nasal polyps. They work differently from other treatments. Nasal polyps are small, noncancerous growths that develop in the ...

Please provide your email address to receive an email when new articles are posted on . Twelve-year data were available for 71 patients, or 85.5% of the assessed study population. Around 55% of those ...

CRSwNP often coexists with asthma, complicating treatment and reducing health-related quality of life. Standard therapies for CRSwNP, like nasal irrigation and corticosteroids, often inadequately ...

AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab -ekko) has been approved in the US for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately ...

The FDA approved Amgen's and AstraZeneca's drug to treat chronic rhinosinusitis with nasal polyps, an inflammatory condition of the sinuses and nasal passages. The companies said the approval was ...